Expanding Clinical Pipeline TREVI is actively advancing its pipeline with plans to initiate a Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis, indicating a significant opportunity to provide specialized clinical trial support, medical devices, or laboratory services tailored to pharmaceutical development.

Strong Financial Position With nearly 195 million USD in cash, cash equivalents, and marketable securities, TREVI is well-positioned to invest in expanding its research activities, technology infrastructure, and strategic partnerships across the biopharmaceutical space.

Focus on Respiratory Therapies TREVI’s focus on developing treatments for respiratory conditions like chronic cough provides an opening for sales opportunities in respiratory health technologies, medical equipment, and digital health solutions targeted at pulmonology clinics and hospitals.

Active Industry Presence Participation in major industry conferences such as CHEST 2025 and ERS 2025 underscores TREVI’s engagement with the respiratory healthcare community, presenting avenues to introduce supporting solutions like medical communications, event technology, or patient engagement tools to enhance their outreach.

Growing Company Profile As a clinical-stage biopharmaceutical enterprise with recent positive earnings reports and strategic R&D updates, TREVI offers potential sales opportunities in biotechnology-focused software, laboratory instrumentation, and compliance solutions aimed at supporting their ongoing research and regulatory activities.